GLP-1 therapy treats a chronic metabolic condition, so many patients continue for a year or longer, with periodic review of dose and goals
Important safety warnings seek urgent medical attention if you experience: Severe or persistent abdominal pain, which may radiate to the back this could indicate pancreatitis , a serious but rare risk associated with GLP-1based therapies as a class [16] [17] Right upper quadrant pain, fever, or jaundice these may suggest gallbladder disease , another class-associated risk Signs of dehydration (dizziness, reduced urine output, extreme thirst) resulting from severe vomiting or diarrhoea, which can affect kidney function Pregnancy and breastfeeding: Use of GLP-1based therapies and related investigational agents is not recommended during pregnancy or breastfeeding
Muscle preservation is supported through adequate protein intake, regular resistance training, and appropriate recovery strategies
Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials
During the study period, three participants discontinued treatment: two due to gastrointestinal adverse effects (nausea and vomiting) and one due to PsO exacerbation [154]
